Daily Roundup

MP1.ASX NDO.ASX AL3.ASX PAR.ASX AI1.ASX

Megaport Secures Major $35.4M Compute Contract

Megaport Limited (ASX: MP1) has announced a significant win for its subsidiary, Latitude.sh. The company has secured a 36-month, $35.4 million compute and storage contract, representing approximately $11.8 million in Annualised Recurring Revenue (ARR). This strategic deal has driven strong growth in Megaport's compute and network businesses, with Compute ARR increasing 31% to $82.7 million and Megaport Network ARR (excluding India) up 20% to $272 million.

Nido Education Expands with $9.1 Million Acquisition

Nido Education Limited (ASX: NDO) has completed the $9.1 million acquisition of four child care services from its incubators. The acquired services have an estimated annualised EBITDA of $1.9 million, an average daily fee of $197, and a total of 348 places. While the sector remains challenging, Nido is maintaining a disciplined approach to site selection and actively assessing acquisition opportunities outside of its greenfield pipeline.

AML3D Secures Major US Navy Orders, Expands Global Footprint

AML3D Limited (ASX: AL3) reported strong quarterly results, with $2.2 million in customer receipts and a total of $29 million in orders on hand. The company received a $9.9 million order from US Navy shipbuilder Newport News Shipbuilding and a $2.6 million order for US Navy submarine components. AML3D is expanding its US facilities to meet growing demand and is also making progress in the UK and European defence markets.

Paradigm Biopharmaceuticals Advances Knee Osteoarthritis Trial

Paradigm Biopharmaceuticals (ASX: PAR) provided an update on its global Phase 3 PARA_OA_012 clinical trial for the treatment of knee osteoarthritis. The company has achieved the milestone of 50% of patients dosed, with interim analysis results expected in Q3 2026. Paradigm also highlighted positive biomarker and translational study publications, supporting the scientific and mechanistic validation of its injectable pentosan polysulfate sodium (iPPS) treatment.

Adisyn Achieves Graphene Milestone, Secures $14 Million Placement

Adisyn Ltd (ASX: AI1) made significant advances in developing graphene-based semiconductor interconnects, including the successful low-temperature deposition of graphene using an industrial ALD system. The company also identified a new graphene application for radar signature reduction and secured a $14 million placement from leading institutional investors to support its technology development and commercialization efforts.